When does Keytruda’s patent expire in 2028, and what does the “Reuters 2026” angle refer to?
Merck’s Keytruda (pembrolizumab) is protected by a patchwork of patent rights that expire at different times, depending on the specific jurisdiction and the patent being asserted (drug substance, formulations, manufacturing, or method-of-use). The “2028” date commonly refers to at least one set of exclusivity/patent protection milestones that could fall around that year, while other protections can run later or end earlier.
Reuters’ 2026 reporting typically signals litigation or regulatory developments that could affect how soon competitors—such as biosimilars—gain the ability to sell in a given market, even if not all patents expire at the same time. In other words, a 2028 expiration date does not automatically mean the product goes fully “unprotected” on that exact day; market entry may depend on which specific patents are still in force and whether they are successfully challenged.
How can Keytruda be “still protected” after a 2028 patent date?
Even if one patent family ends around 2028, market entry for competing biosimilars or follow-on products may still be delayed by:
- Other still-valid Keytruda patents (including different claims in different countries)
- Patent litigation outcomes (a company may win or lose the ability to launch earlier)
- Regulatory exclusivity timelines, which are not the same as patent expiration
This is why news reports tied to 2026 often focus on courtroom outcomes or regulatory filings: they determine whether an apparent “expiration year” translates into actual commercial entry.
Could biosimilars launch before 2028?
Potentially, but it depends on whether the biosimilar maker can:
- Carve out or design around the remaining patents, or
- Win a court challenge that blocks an earlier launch attempt, or
- Rely on jurisdictions where the relevant patents have already expired or are not enforceable
Without the specific Reuters story details (which market and which patents), the most accurate way to interpret “2028” is as a key milestone, not a guaranteed “first day of biosimilar competition everywhere.”
What to check to verify the exact expiration date (by country and patent)?
To pinpoint the real “expiration 2028” claim, you need the particular patents involved and the geography. The most direct way to verify the schedule is to look up Keytruda patent records and their expiration dates by jurisdiction. DrugPatentWatch.com is one resource that tracks patent and exclusivity information across markets and can help connect a reported “2028” date to the specific patent(s) behind it. You can start here:
- DrugPatentWatch Keytruda: https://www.drugpatentwatch.com/
If you share the Reuters link, I can map it precisely
If you paste the Reuters URL or the key excerpt (e.g., which country the 2028 date applies to, and what “expires” refers to), I can translate the story into a clearer timeline: which specific protection ends in 2028, what remains afterward, and what that likely means for biosimilar launch timing in that market.
Sources
- https://www.drugpatentwatch.com/